CRISPR Therapeutics announced it will present clinical trial data for zugocabtagene geleucel (zugo-cel), an allogeneic CRISPR/Cas9 gene-edited CAR T cell therapy targeting CD19, at the 68th ASH Annual Meeting in December 2026. The therapy is being tested in patients with relapsed or refractory large B-cell lymphoma and shows dose-dependent efficacy. Zugo-cel is an off-the-shelf treatment designed to enhance immune response without needing HLA matching. This presentation highlights CRISPR Therapeutics' progress in developing innovative gene-based treatments for cancer and autoimmune diseases.
CRISPR Therapeutics (CRSP) shares rose 3.10% to USD 51.54 as of Nov 04, 2026 21:11 WIB on Pluang. The stock trades between USD 44.34 and USD 61.89 over the past year. Despite a 100% sell order activity on Pluang, the market cap stands at $4.83 billion, showing strong investor interest in gene-editing therapies.
CRISPR Therapeutics reported strong Q3 2026 financial results, with CASGEVY revenue reaching $99 million, up 30% from the previous quarter and nearly six times Q3 2025. The gene-editing therapy CASGEVY gained new approvals for younger children in the...
CRISPR Therapeutics has named Dr. Siva Sakhamuri as its new Chief Technical Officer, effective immediately. Dr. Sakhamuri brings nearly 30 years of experience in biologics, RNA therapeutics, and vaccine manufacturing, having held leadership roles at ...
